Triphenylphosphine oxide is a potent and selective inhibitor of the transient receptor potential melastatin-5 ion channel

RK Palmer, K Atwal, I Bakaj… - Assay and drug …, 2010 - liebertpub.com
RK Palmer, K Atwal, I Bakaj, S Carlucci-Derbyshire, MT Buber, R Cerne, RY Cortés…
Assay and drug development technologies, 2010liebertpub.com
Transient receptor potential melastatin-5 (TRPM5) is a calcium-gated monovalent cation
channel expressed in highly specialized cells of the taste bud and gastrointestinal tract, as
well as in pancreatic β-cells. Well established as a critical signaling protein for G protein-
coupled receptor–mediated taste pathways, TRPM5 also has recently been implicated as a
regulator of incretin and insulin secretion. To date, no inhibitors of practical use have been
described that could facilitate investigation of TRPM5 functions in taste or secretion of …
Abstract
Transient receptor potential melastatin-5 (TRPM5) is a calcium-gated monovalent cation channel expressed in highly specialized cells of the taste bud and gastrointestinal tract, as well as in pancreatic β-cells. Well established as a critical signaling protein for G protein-coupled receptor–mediated taste pathways, TRPM5 also has recently been implicated as a regulator of incretin and insulin secretion. To date, no inhibitors of practical use have been described that could facilitate investigation of TRPM5 functions in taste or secretion of metabolic hormones. Using recombinant TRPM5-expressing cells in a fluorescence imaging plate reader-based membrane potential assay, we identified triphenylphosphine oxide (TPPO) as a selective and potent inhibitor of TRPM5. TPPO inhibited both human (IC50 = 12 μM) and murine TRPM5 (IC50 = 30 μM) heterologously expressed in HEK293 cells, but had no effect (up to 100 μM) on the membrane potential responses of TRPA1, TRPV1, or TRPM4b. TPPO also inhibited a calcium-gated TRPM5-dependent conductance in taste cells isolated from the tongues of transgenic TRPM5+/− mice. In contrast, TPP had no effect on TRPM5 responses, indicating a strict requirement of the oxygen atom for activity. Sixteen additional TPPO derivatives also inhibited TRPM5 but none more potently than TPPO. Structure–activity relationship of tested compounds was used for molecular modeling-based analysis to clarify the positive and negative structural contributions to the potency of TPPO and its derivatives. TPPO is the most potent TRPM5 inhibitor described to date and is the first demonstrated to exhibit selectivity over other channels.
Mary Ann Liebert